Vertex EVP granted performance-based stock awards

Vertex Pharmaceuticals executive Amit Sachdev reported new stock awards tied to performance goals.

Rhea-AI Filing Summary

Vertex Pharmaceuticals executive Amit Sachdev reported new stock awards tied to performance goals. On 01/22/2026, he acquired 7,866 shares of Vertex common stock and another 3,883 shares at a price of $0 per share, reflecting earned performance stock unit awards granted on 02/01/2023 and 02/12/2025 after the compensation committee certified goal attainment on 01/22/2026. Following these awards, he directly holds 70,998 common shares, with additional indirect holdings of 882 shares in a 401(k) plan and 9,301 shares held in trust. The earned performance shares are scheduled to vest on 02/13/2026 and in installments beginning on 02/24/2026.

Insider Trade Summary

Grant/Award: 11,749 shares

Grant/Award 4 txns

Insider Sachdev Amit

Role EVP Chief Patient & Ext Af Off

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	7,866	$0.00	$0.00
Grant/Award	Common Stock	3,883	$0.00	$0.00
holding	Common Stock	--	--	--
holding	Common Stock	--	--	--

Holdings After Transaction: Common Stock — 70,998 shares (Direct); Common Stock — 882 shares (Indirect, 401(k)); Common Stock — 9,301 shares (Indirect, Held in Trust)

Footnotes (2)

1. F1. Represents earned performance shares with respect to a performance stock unit award granted on 02/01/2023 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 01/22/2026 and the shares will vest on 02/13/2026.
2. F2. Represents earned performance shares with respect to a performance stock unit award granted on 02/12/2025 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 01/22/2026 and the shares will vest in installments beginning on 02/24/2026.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider activity did Vertex (VRTX) report for Amit Sachdev?

On 01/22/2026, EVP Chief Patient & External Affairs Officer Amit Sachdev reported the acquisition of 7,866 and 3,883 shares of Vertex common stock tied to performance stock unit awards at $0 per share.

How many Vertex (VRTX) shares does Amit Sachdev own after this Form 4?

After the reported transactions, Amit Sachdev directly owns 70,998 shares of Vertex common stock, plus 882 shares indirectly via a 401(k) and 9,301 shares held in trust.

What triggered the share awards reported in this Vertex (VRTX) Form 4?

The shares represent earned performance shares from performance stock unit awards granted on 02/01/2023 and 02/12/2025, after the compensation committee certified performance-goal attainment on 01/22/2026.

When will the newly earned Vertex (VRTX) performance shares vest?

The performance shares tied to the 02/01/2023 grant will vest on 02/13/2026, and those from the 02/12/2025 grant will vest in installments beginning on 02/24/2026.

Did Amit Sachdev buy Vertex (VRTX) shares on the open market?

No. The Form 4 shows shares acquired at a price of $0 per share as earned performance stock awards, not open-market purchases.

What is Amit Sachdev’s role at Vertex (VRTX)?

Amit Sachdev is an officer of Vertex Pharmaceuticals, serving as EVP Chief Patient & External Affairs Officer as indicated in the filing.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 01/26/2026 - 04:35 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Sachdev Amit

(Last) (First) (Middle)

C/O VERTEX PHARMACEUTICALS INCORPORATED

50 NORTHERN AVENUE

(Street)

BOSTON MA 02210

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
VERTEX PHARMACEUTICALS INC / MA [ VRTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP Chief Patient & Ext Af Off

3. Date of Earliest Transaction (Month/Day/Year)
01/22/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/22/2026		A		7,866(1)	A	$0	67,115	D
Common Stock	01/22/2026		A		3,883(2)	A	$0	70,998	D
Common Stock								882	I	401(k)
Common Stock								9,301	I	Held in Trust

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents earned performance shares with respect to a performance stock unit award granted on 02/01/2023 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 01/22/2026 and the shares will vest on 02/13/2026.

2. Represents earned performance shares with respect to a performance stock unit award granted on 02/12/2025 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 01/22/2026 and the shares will vest in installments beginning on 02/24/2026.

Remarks:

	/s/ Christiana Stevenson, Attorney-in-Fact	01/26/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.